Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

The Association of Anemia and Patient Reported Outcomes in the New Era of PNH Treatment

Blood (2024) 144 (Supplement 1): 2321.

https://doi.org/10.1182/blood-2024-204693

Published: 2024

Journal Articles

Reaction - Real Life Use of Ravulizumab in Italian Patients with Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study, Final Results

Blood (2024) 144 (Supplement 1): 2464.

https://doi.org/10.1182/blood-2024-204659

Published: 2024

Journal Articles

Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial

Blood (2023) 142 (Supplement 1): 571.

https://doi.org/10.1182/blood-2023-180780

Published: 2023

Journal Articles

Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study

Blood (2022) 140 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2022-171469

Published: 2022

Journal Articles

Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)

Luca Lanino, Prassede Salutari, Alessandra Perego, Bruno Fattizzo, Marta Riva, Marta Ubezio, Pellegrino Musto, Daniela Cilloni, Esther Natalie Oliva, Maria Teresa Voso, Anna Maria Pelizzari, Antonella Poloni, Isabella Capodanno, Chiara Elena, Claudio Fozza, Fabrizio Pane, Massimo Breccia, Marco De Gobbi, Francesco Di Bassiano, Daniela Barraco, Elena Crisà, Dario Ferrero, Chiara Frairia, Antonella Vaccarino, Davide Griguolo, Stefania Paolini, Martina Quintini, Mariarosaria Sessa, Mauro Turrini, Monica Bocchia, Nicola Di Renzo, Elisa Diral, Cristina Foli, Alfredo Molteni, Ubaldo Occhini, Giulia Rivoli, Carmine Selleri, Roberto Bono, Anna Calvisi, Andrea Castelli, Eros Di Bona, Ambra Di Veroli, Luana Fianchi, Sara Galimberti, Daniele Grimaldi, Monia Marchetti, Marianna Norata, Alessandro Rambaldi, Ilaria Tanasi, Patrizia Tosi, Ilaria Naldi, Valeria Santini, Matteo G. Della Porta

Blood (2022) 140 (Supplement 1): 6945–6948.

https://doi.org/10.1182/blood-2022-164559

Published: 2022

Journal Articles

Sars-Cov-2 Vaccination in Patients with Paroxysmal Nocturnal Hemoglobinuria: An Italian Multicenter Survey

Juri Alessandro Giannotta, Bruno Fattizzo, Corrado Girmenia, Claudia Ielo, Elisabetta Metafuni, Adele Visentin, Paola Bianchi, Vincenzo Apolito, Eloise Beggiato, Eros Di Bona, Simona Sica, Anna Paola Iori, Wilma Barcellini

Blood (2021) 138 (Supplement 1): 2180.

https://doi.org/10.1182/blood-2021-150328

Published: 2021

Journal Articles

Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation

Blood (2020) 136 (19): 2237–2240.

https://doi.org/10.1182/blood.2019004371

Published: 2020

Includes: Supplemental data

Journal Articles

Clinical Benefit of Crenolanib, with or without Salvage Chemotherapy, in Multiply Relapsed, FLT3 Mutant AML Patients after Prior Treatment with Gilteritinib

Aaron D Goldberg, MDPhD, Mark B. Geyer, MD, Jonathan Kell, MD, Eros Di Bona, MD, Timothy S. Pardee, MDPhD, Rupali Bhave, MD, Michael R. Grunwald, MD, Giovanni Marconi, MD, Yijia Wang, MD MPH, Asif Pathan, PhD RPh, Boo Messahel, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-139898

Published: 2020

Journal Articles

Serological Prevalence of Sars-Cov-2 Infection Among Chronic Myeloid Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Treatment in Italy (COVID-19-HEM Study)

Blood (2020) 136 (Supplement 1): 42.

https://doi.org/10.1182/blood-2020-140032

Published: 2020

Journal Articles

COVID-19 Infection in Patients with Paroxysmal Nocturnal Hemoglobinuria in Italy

Wilma Barcellini, Bruno Fattizzo, MD, Luisa Quattrocchi, Juri Alessandro Giannotta, MD, Semra Aydin, MD PhD, Federica Barone, MD, Cecilia Carbone, MD, Eloise Beggiato, Paola Bianchi, BSc, PhD, Eros Di Bona, MD, Rosario Notaro, MD, Anna Paola Iori

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-138721

Published: 2020

Journal Articles

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

Simona Soverini, Luana Bavaro, Caterina De Benedittis, Margherita Martelli, Alessandra Iurlo, Nicola Orofino, Simona Sica, Federica Sorà, Francesca Lunghi, Fabio Ciceri, Sara Galimberti, Claudia Baratè, Massimiliano Bonifacio, Luigi Scaffidi, Fausto Castagnetti, Gabriele Gugliotta, Francesco Albano, Antonella Vita Russo Rossi, Fabio Stagno, Francesco di Raimondo, Mariella D’Adda, Eros di Bona, Elisabetta Abruzzese, Gianni Binotto, Rosaria Sancetta, Marzia Salvucci, Isabella Capodanno, Mariella Girasoli, Sabrina Coluzzi, Immacolata Attolico, Caterina Musolino, Elisabetta Calistri, Mario Annunziata, Monica Bocchia, Stefania Stella, Anna Serra, Santa Errichiello, Giuseppe Saglio, Fabrizio Pane, Paolo Vigneri, Flavio Mignone, Maria Antonella Laginestra, Stefano Aldo Pileri, Antonio Percesepe, Elena Tenti, Gianantonio Rosti, Michele Baccarani, Michele Cavo, Giovanni Martinelli

Blood (2020) 135 (8): 534–541.

https://doi.org/10.1182/blood.2019002969

Published: 2020

Includes: Supplemental data

Journal Articles

Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR

Elisa Diral, MD, Philipp Le Coutre, MD, Enrico Marco Gottardi, Chiara Elena, MD, Micaela Bergamaschi, MD, Sarit Assouline, MD, Eros Di Bona, MD, Jessica Petiti, PhD, Fabio Stagno, MD, Alessandra Iurlo, MD PhD, Dong-Wook Kim, Alessandra Pirola, MSc, Maria Luisa Bonanomi, Patrizia Crivori, PhD, Rocco Piazza, MD PhD, Carmen Fava, Carlo Gambacorti-Passerini, MD

Blood (2019) 134 (Supplement_1): 29.

https://doi.org/10.1182/blood-2019-125226

Published: 2019

Journal Articles

Low-dose rituximab in autoimmune hemolytic anemia: 10 years after

Bruno Fattizzo, Anna Zaninoni, Loredana Pettine, Francesca Cavallaro, Eros Di Bona, Wilma Barcellini

Blood (2019) 133 (9): 996–998.

https://doi.org/10.1182/blood-2018-12-885228

Published: 2019

Journal Articles

Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing

Simona Soverini, PhD, Luana Bavaro, Margherita Martelli, Caterina De Benedittis, PhD, Alessandra Iurlo, Nicola Orofino, MD, Livio Pagano, Marianna Criscuolo, Massimiliano Bonifacio, Luigi Scaffidi, MD, Simona Sica, MD, Federica Sorà, MD, Elena Maino, Michela Rondoni, MD, Maria Antonella Laginestra, PhD, Francesca Lunghi, Anna Ermacora, Mariella D'adda, MD, Gabriele Gugliotta, MD PhD, Fausto Castagnetti, Gianantonio Rosti, Cristina Papayannidis, Giovanni Marconi, Antonio Curti, Maria Cristina Miggiano, Sara Galimberti, Antonio Percesepe, MD PhD, Fabio Stagno, Rosaria Sancetta, MD, Mario Annunziata, Franca Falzetti, MD, Isabella Capodanno, Patrizia Pregno, Margherita Maffioli, MD, Tamara Intermesoli, MD, Eros Di Bona, MD, Giovanni Caocci, MD, Imma Attolico, MD, Gianni Binotto, Monica Bocchia, MD PhD, Emanuele Angelucci, MD, Nicola Sgherza, MD, Luigiana Luciano, Flavio Mignone, Stefano A. Pileri, MD PhD, Giovanni Martinelli, Michele Cavo, MD

Blood (2018) 132 (Supplement 1): 789.

https://doi.org/10.1182/blood-2018-99-117166

Published: 2018

Journal Articles

Imatinib Suspension and Validation (ISAV) Study: Final Results at 79 Months

Blood (2018) 132 (Supplement 1): 461.

https://doi.org/10.1182/blood-2018-99-112982

Published: 2018

Journal Articles

Imatinib Suspension and Validation Study: Results from the Isav Study at 62 Months

Blood (2017) 130 (Supplement 1): 2870.

https://doi.org/10.1182/blood.V130.Suppl_1.2870.2870

Published: 2017

Journal Articles

What's Next in CML - a Prospective Study Evaluating Sanger Sequencing and Next Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain (KD) Mutation Screening

Simona Soverini, PhD, Luana Bavaro, Caterina De Benedittis, PhD, Margherita Martelli, Stefania Stella, PhD, Paolo Vigneri, MD PhD, Alessandra Iurlo, MD PhD, Nicola Orofino, MD, Simona Sica, MD, Federica Sorà, MD, Sara Galimberti, PhD MD, Claudia Baratè, MD PhD, Francesco Albano, MD, Antonella Russo Rossi, MD, Fabio Ciceri, MD, Francesca Lunghi, MD, Fausto Castagnetti, MD, Gabriele Gugliotta, MD PhD, Gianantonio Rosti, MD, Elena Tenti, PhD, Fabio Stagno, MD PhD, Elisabetta Novella, PhD, Eros Di Bona, MD, Massimiliano Bonifacio, MD, Elisabetta Abruzzese, MD PhD, Marzia Salvucci, MD, Mariella D'Adda, MD, Rosaria Sancetta, MD, Elisabetta Calistri, MD, Monica Bocchia, Isabella Capodanno, MD, Giuseppina Spinosa, MD, Maria Antonella Laginestra, PhD, Santa Errichiello, PhD, Anna Serra, Dr, Francesca Carnuccio, Dr, Sabrina Coluzzi, PhD, Mario Annunziata, MD, Caterina Musolino, MD, Fabrizio Pane, MD, Giuseppe Saglio, MD PhD, Michele Baccarani, MD, Michele Cavo, MD, Giovanni Martinelli, MD

Blood (2017) 130 (Supplement 1): 248.

https://doi.org/10.1182/blood.V130.Suppl_1.248.248

Published: 2017

Journal Articles

Prospective Evaluation of Thrombo-Hemorrhagic Events and Hypercoagulation Markers in Patients with Acute Promyelocytic Leukemia (APL) Receiving All-Trans Retinoic Acid (ATRA) Plus Chemotherapy

Anna Falanga, MD, Laura Russo, Marina Marchetti, Carmen J Tartari, Laura Castellani, Eros Di Bona, MD, Barry Woodhams, PhD MPhil, Alessandro Rambaldi, MD Prof, Francesco Lo Coco, MD

Blood (2017) 130 (Supplement 1): 3694.

https://doi.org/10.1182/blood.V130.Suppl_1.3694.3694

Published: 2017

Journal Articles

Efficacy and Safety of Decitabine As First-Line Therapy for Elderly Patients with Acute Myeloid Leukemia.a Real Life Multicentric Experience of the Northern Italy

Blood (2017) 130 (Supplement 1): 1315.

https://doi.org/10.1182/blood.V130.Suppl_1.1315.1315

Published: 2017

Journal Articles

Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL)

Blood (2016) 128 (22): 176.

https://doi.org/10.1182/blood.V128.22.176.176

Published: 2016

NARROW

The Association of Anemia and Patient Reported Outcomes in the New Era of PNH Treatment

Reaction - Real Life Use of Ravulizumab in Italian Patients with Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study, Final Results

Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial

Sars-Cov-2 Vaccination in Patients with Paroxysmal Nocturnal Hemoglobinuria: An Italian Multicenter Survey

Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation

Clinical Benefit of Crenolanib, with or without Salvage Chemotherapy, in Multiply Relapsed, FLT3 Mutant AML Patients after Prior Treatment with Gilteritinib

Serological Prevalence of Sars-Cov-2 Infection Among Chronic Myeloid Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Treatment in Italy (COVID-19-HEM Study)

COVID-19 Infection in Patients with Paroxysmal Nocturnal Hemoglobinuria in Italy

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR

Low-dose rituximab in autoimmune hemolytic anemia: 10 years after

Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing

Imatinib Suspension and Validation (ISAV) Study: Final Results at 79 Months

Imatinib Suspension and Validation Study: Results from the Isav Study at 62 Months

What's Next in CML - a Prospective Study Evaluating Sanger Sequencing and Next Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain (KD) Mutation Screening

Prospective Evaluation of Thrombo-Hemorrhagic Events and Hypercoagulation Markers in Patients with Acute Promyelocytic Leukemia (APL) Receiving All-Trans Retinoic Acid (ATRA) Plus Chemotherapy

Efficacy and Safety of Decitabine As First-Line Therapy for Elderly Patients with Acute Myeloid Leukemia.a Real Life Multicentric Experience of the Northern Italy

Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only